Treatment of Idiopathic Pulmonary Fibrosis With Thalidomide
Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to determine whether thalidomide can stop the progression of
fibrosis in IPF.
The primary objective of this study is to determine the safety, feasibility and efficacy of
400 mg of thalidomide administered daily for one year in patients with idiopathic pulmonary
fibrosis (IPF) who have failed or are not candidates for treatment with corticosteroids
and/or cytotoxic drugs.
The study population will consist of patients with biopsy-proven moderate to severe IPF who
have failed or are not candidates for standard therapy with corticosteroids and/or cytotoxic
drugs.